KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agilent Technologies (A) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for Agilent Technologies (A) over the last 17 years, with Q4 2025 value amounting to $15.0 million.

  • Agilent Technologies' Asset Writedowns and Impairment rose 2500.0% to $15.0 million in Q4 2025 from the same period last year, while for Oct 2025 it was $45.0 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $45.0 million for FY2025, which is 0.0% changed from last year.
  • Agilent Technologies' Asset Writedowns and Impairment amounted to $15.0 million in Q4 2025, which was up 2500.0% from $8.0 million recorded in Q3 2025.
  • Agilent Technologies' 5-year Asset Writedowns and Impairment high stood at $262.0 million for Q3 2023, and its period low was $2.0 million during Q2 2021.
  • Its 5-year average for Asset Writedowns and Impairment is $24.8 million, with a median of $9.0 million in 2021.
  • Per our database at Business Quant, Agilent Technologies' Asset Writedowns and Impairment crashed by 9797.98% in 2021 and then skyrocketed by 5714.29% in 2024.
  • Agilent Technologies' Asset Writedowns and Impairment (Quarter) stood at $8.0 million in 2021, then changed by 0.0% to $8.0 million in 2022, then soared by 3175.0% to $262.0 million in 2023, then crashed by 95.42% to $12.0 million in 2024, then rose by 25.0% to $15.0 million in 2025.
  • Its Asset Writedowns and Impairment stands at $15.0 million for Q4 2025, versus $8.0 million for Q3 2025 and $12.0 million for Q2 2025.